Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $49.10, for a total transaction of $736,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00.
• On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.02, for a total transaction of $690,300.00.
• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Stock Down 2.8%

Shares of Maze Therapeutics stock opened at $48.03 on Friday. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $53.65. The stock has a market cap of $2.31 billion, a PE ratio of -2.30 and a beta of 4.47. The business has a fifty day simple moving average of $45.84 and a 200-day simple moving average of $36.97.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MAZE shares. Guggenheim raised their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target on the stock. BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Monday, March 9th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $58.56.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc acquired a new stake in Maze Therapeutics in the 2nd quarter worth approximately $227,000. Frazier Life Sciences Management L.P. raised its position in shares of Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after purchasing an additional 438,274 shares during the period. Washington University bought a new position in shares of Maze Therapeutics in the third quarter valued at approximately $5,463,000. ArrowMark Colorado Holdings LLC acquired a new stake in shares of Maze Therapeutics in the third quarter worth $14,135,000. Finally, Virtus Investment Advisers LLC bought a new stake in shares of Maze Therapeutics during the 2nd quarter worth $85,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.